Related Experiment Video
Updated: Jul 10, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Lamotrigine extended-release as adjunctive therapy for partial seizures
D K Naritoku1, C R Warnock, J A Messenheimer
1Department of Neurology, Southern Illinois University, PO Box 19637, Springfield, IL 62794-9637, USA. dnaritoku@siumed.edu
Neurology
|October 17, 2007
Summary
Adjunctive lamotrigine extended-release (XR) significantly reduced partial seizure frequency in epilepsy patients. This new once-daily formulation was well-tolerated and effective, supporting its clinical use.
Area of Science:
- Neurology
- Epileptology
- Pharmacology
Background:
- Epilepsy is a neurological disorder characterized by recurrent seizures.
- Partial seizures are a common type of epilepsy requiring effective adjunctive treatments.
Purpose of the Study:
- To assess the efficacy and tolerability of once-daily lamotrigine extended-release (XR) as adjunctive therapy for partial seizures.
- To evaluate the safety profile of lamotrigine XR in epilepsy patients.
Main Methods:
- A double-blind, parallel-group trial randomized patients over 12 years old with partial seizures to receive adjunctive lamotrigine XR or placebo.
- The study included a baseline phase, a 7-week escalation phase, and a 12-week maintenance phase.
Main Results:
- Lamotrigine XR demonstrated a significantly greater median percent reduction in weekly partial seizure frequency compared to placebo (46.6% vs 24.5%, p=0.0001).
- A higher percentage of patients on lamotrigine XR achieved at least a 50% seizure reduction (44.0% vs 20.8%, p=0.0002).
- Common adverse events included headache and dizziness, with no significant differences in health outcomes between groups.
Conclusions:
- Once-daily adjunctive lamotrigine XR effectively reduces partial seizure frequency in epilepsy patients.
- The extended-release formulation of lamotrigine was well-tolerated, supporting its clinical utility.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...